FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150278482> ?p ?o ?g. }

• W2150278482 endingPage "e472" @default.
• W2150278482 startingPage "e466" @default.
• W2150278482 abstract "OBJECTIVE. Insulin glargine is difficult to use for children due to the number of injections required because it is claimed to be immiscible with rapid-acting insulin analogs. For this study, we hypothesized that treating new-onset type 1 diabetes with twice-daily insulin glargine plus a rapid-acting insulin analog mixed in the same syringe would result in better glycosylated hemoglobin than twice-daily neutral protamine Hagedorn with a rapid-acting insulin analog (standard treatment). METHODS. Forty-two patients with new-onset type 1 diabetes were started on standard treatment. Three months after diagnosis, if patients were found compliant and had a glycosylated hemoglobin level of ≤9%, then they were randomly assigned either to receive insulin glargine twice daily mixed with a rapid-acting insulin analog or to continue on standard treatment for 3 more months. Additional lunchtime rapid-acting insulin analog injections were given for the insulin glargine group as necessary. RESULTS. Nineteen patients in the insulin glargine group and 17 in the neutral protamine Hagedorn group completed the study. The glycosylated hemoglobin level at baseline was 6.8% ± 1% vs 6.9% ± 1% and at poststudy was 6.7% ± 1.3% vs 7.6% ± 1% in the insulin glargine versus neutral protamine Hagedorn group, respectively. Two patients in the insulin glargine group required lunch rapid-acting insulin analog in the last month of the study. Although both groups were encouraged to contact the principal investigator with all queries, more in the insulin glargine arm opted to do so. CONCLUSIONS. Glycemic control with insulin glargine mixed with a rapid-acting insulin analog given twice daily seems significantly more effective than the standard therapy in newly diagnosed type 1 diabetes. Furthermore, it decreases pain and burden of injections for children with diabetes by allowing patients to mix glargine with rapid-acting insulin analog." @default.
• W2150278482 created "2016-06-24" @default.
• W2150278482 creator A5000711805 @default.
• W2150278482 creator A5001152901 @default.
• W2150278482 creator A5011531976 @default.
• W2150278482 creator A5048391106 @default.
• W2150278482 creator A5084519276 @default.
• W2150278482 date "2008-03-01" @default.
• W2150278482 modified "2023-10-16" @default.
• W2150278482 title "A Randomized, Controlled Trial Comparing Twice-a-Day Insulin Glargine Mixed With Rapid-Acting Insulin Analogs Versus Standard Neutral Protamine Hagedorn (NPH) Therapy in Newly Diagnosed Type 1 Diabetes" @default.
• W2150278482 cites W1521212699 @default.
• W2150278482 cites W1652659703 @default.
• W2150278482 cites W1965270239 @default.
• W2150278482 cites W1971493468 @default.
• W2150278482 cites W1988396627 @default.
• W2150278482 cites W1990624369 @default.
• W2150278482 cites W1997676993 @default.
• W2150278482 cites W2006539813 @default.
• W2150278482 cites W2016218743 @default.
• W2150278482 cites W2020483344 @default.
• W2150278482 cites W2036205080 @default.
• W2150278482 cites W2040587697 @default.
• W2150278482 cites W2059989157 @default.
• W2150278482 cites W2080393128 @default.
• W2150278482 cites W2081135787 @default.
• W2150278482 cites W2086666326 @default.
• W2150278482 cites W2096093351 @default.
• W2150278482 cites W2108534942 @default.
• W2150278482 cites W2115022001 @default.
• W2150278482 cites W2139476196 @default.
• W2150278482 cites W2149253043 @default.
• W2150278482 cites W2152709499 @default.
• W2150278482 cites W2158144637 @default.
• W2150278482 cites W2160880263 @default.
• W2150278482 cites W2168448906 @default.
• W2150278482 cites W2168959099 @default.
• W2150278482 cites W2170045262 @default.
• W2150278482 cites W2312297815 @default.
• W2150278482 cites W2323149989 @default.
• W2150278482 cites W2769264260 @default.
• W2150278482 cites W4234329496 @default.
• W2150278482 cites W4252271922 @default.
• W2150278482 cites W4367484408 @default.
• W2150278482 doi "https://doi.org/10.1542/peds.2007-1679" @default.
• W2150278482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18299307" @default.
• W2150278482 hasPublicationYear "2008" @default.
• W2150278482 type Work @default.
• W2150278482 sameAs 2150278482 @default.
• W2150278482 citedByCount "32" @default.
• W2150278482 countsByYear W21502784822012 @default.
• W2150278482 countsByYear W21502784822013 @default.
• W2150278482 countsByYear W21502784822014 @default.
• W2150278482 countsByYear W21502784822015 @default.
• W2150278482 countsByYear W21502784822016 @default.
• W2150278482 countsByYear W21502784822018 @default.
• W2150278482 countsByYear W21502784822021 @default.
• W2150278482 countsByYear W21502784822022 @default.
• W2150278482 crossrefType "journal-article" @default.
• W2150278482 hasAuthorship W2150278482A5000711805 @default.
• W2150278482 hasAuthorship W2150278482A5001152901 @default.
• W2150278482 hasAuthorship W2150278482A5011531976 @default.
• W2150278482 hasAuthorship W2150278482A5048391106 @default.
• W2150278482 hasAuthorship W2150278482A5084519276 @default.
• W2150278482 hasConcept C126322002 @default.
• W2150278482 hasConcept C134018914 @default.
• W2150278482 hasConcept C2776664568 @default.
• W2150278482 hasConcept C2777180221 @default.
• W2150278482 hasConcept C2777557582 @default.
• W2150278482 hasConcept C2778804033 @default.
• W2150278482 hasConcept C2778917026 @default.
• W2150278482 hasConcept C2779306644 @default.
• W2150278482 hasConcept C2779920387 @default.
• W2150278482 hasConcept C2780473172 @default.
• W2150278482 hasConcept C2780668416 @default.
• W2150278482 hasConcept C2780835560 @default.
• W2150278482 hasConcept C2781232474 @default.
• W2150278482 hasConcept C3019948211 @default.
• W2150278482 hasConcept C555293320 @default.
• W2150278482 hasConcept C71924100 @default.
• W2150278482 hasConceptScore W2150278482C126322002 @default.
• W2150278482 hasConceptScore W2150278482C134018914 @default.
• W2150278482 hasConceptScore W2150278482C2776664568 @default.
• W2150278482 hasConceptScore W2150278482C2777180221 @default.
• W2150278482 hasConceptScore W2150278482C2777557582 @default.
• W2150278482 hasConceptScore W2150278482C2778804033 @default.
• W2150278482 hasConceptScore W2150278482C2778917026 @default.
• W2150278482 hasConceptScore W2150278482C2779306644 @default.
• W2150278482 hasConceptScore W2150278482C2779920387 @default.
• W2150278482 hasConceptScore W2150278482C2780473172 @default.
• W2150278482 hasConceptScore W2150278482C2780668416 @default.
• W2150278482 hasConceptScore W2150278482C2780835560 @default.
• W2150278482 hasConceptScore W2150278482C2781232474 @default.
• W2150278482 hasConceptScore W2150278482C3019948211 @default.
• W2150278482 hasConceptScore W2150278482C555293320 @default.
• W2150278482 hasConceptScore W2150278482C71924100 @default.
• W2150278482 hasIssue "3" @default.
• W2150278482 hasLocation W21502784821 @default.
• W2150278482 hasLocation W21502784822 @default.

• next